Selecting the optimal parameters for sonoporation of pancreatic cancer in a pre-clinical model
Christopher W. Schultz, Gorka Ruíz de Garibay, Anika Langer, Ji‐Bin Liu, Teena Dhir, Calum Leitch, Corinne E. Wessner, Mireia Mayoral, Bo Zhang, Mihaela Popa, Chunwang Huang, Spiros Kotopoulis, Xianghong Luo, Yanhua Zhen, Sihua Niu, Mehnoosh Torkzaban, Kirk Wallace, John R. Eisenbrey, Jonathan R. Brody, Emmet McCormack, Flemming Forsberg
Abstract
< .03). Overall, the higher power ultrasound treatment modality was more consistently effective at decreasing tumor volume and increasing vascularity characteristics. In conclusion, Sonazoid was the most consistently effective UCA at decreasing tumor volume and increasing vascularity. Thus, we are pursuing a larger phase II clinical trial to validate the increased efficacy of sonoporation in conjunction with chemotherapy in PDAC patients.